Creative Planning
ARGS

Creative Planning’s Argos Therapeutics, Inc. ARGS Stock Holding History

Creative Planning’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-300
Closed -$2K – 4702
2017
Q2 		$2K Sell
300
-151
-33% -$1.29K ﹤0.01% 4392
2017
Q1 		$4K Buy
451
+150
+50% +$9.49K ﹤0.01% 4121
2016
Q4 		$30K Buy
+301
New +$28.2K ﹤0.01% 2810

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
KeyBank National Association
KeyBank National Association Cleveland, Ohio $27.4B AUM 24.17% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Creative Planning's ARGS Position: Q3 2017 in Review

Creative Planning sold out of Argos Therapeutics, Inc. (ARGS) in Q3 2017, closing a stake of 300 shares — an estimated $2K sold.

Creative Planning first reported a position in ARGS in Q4 2016 and held it in 3 quarters. The position peaked at $30K in Q4 2016. 29 funds tracked by Wall St. Rank hold ARGS as of Q3 2017.

  • Creative Planning reported no remaining Argos Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Creative Planning sold 300 Argos Therapeutics, Inc. shares in Q3 2017, an estimated $2K.
  • Creative Planning first reported a position in Argos Therapeutics, Inc. in Q4 2016 and held it in 3 quarters.
  • Creative Planning's Argos Therapeutics, Inc. position peaked at $30K in Q4 2016.
  • 29 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q3 2017.

Based on Creative Planning's 13F filing for Q3 2017, filed 17 Oct 2017.